Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Percutaneous Coronary Intervention Not Inferior to Bypass Grafting in Diabetic Patients With Multivessel Disease: Presented at ESC - (DGDispatch)
    Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis - (BMJ)
    TopAbstracts in Diabetes 09/02/2008 - (DGNews)
    Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events - (N Engl J Med)
    Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Diabetes
      Cardiometabolic Risk and Risk Management
      An Evolving Approach to the Treatment of Type 2 Diabetes
      Obesity, Type 2 Diabetes, and Cardiovascular Disease
      Global Perspectives on Diabetic Retinopathy: More Than Meets the Eye
      Type 1 Diabetes - New Insights into Pathophysiology, Treatment, and the Search for a Cure

      Webcasts/CME archive

       Recent cases - Diabetes
        Diabetic Fetopathy Associated with Bilateral Adrenal Hyperplasia and Ambiguous Genitalia: A Case Report
        Somatostatinoma: A Rare Cause of Diabetic Ketosis
        New Onset Diabetes Complicated by Haemolysis and Rhabdomyolysis: A Case Report and Review of the Literature
        Diabetic Control and Atypical Antipsychotics: A Case Report
        Treatment with Pioglitazone Induced Significant, Reversible Mitral Regurgitation

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Orlistat Found Beneficial in Type 2 Diabetics with Differing Hemoglobin A1c Levels: Presented at ADA

        By Jill Stein
        Special to DG News

        SAN FRANCISCO, CA -- June 19, 2002 -- Orlistat used in conjunction with diet is a valuable adjunctive therapy in overweight and obese type 2 diabetics at all levels of glycemic control, researchers announced at the 62nd Scientific Sessions of the American Diabetes Association (ADA).

        Dr. Ralph De Fronzo, from the University of Texas Health Science Center in San Antonio, Texas, United States, presented the results of a retrospective analysis that examined the effect of orlistat on hemoglobin A1c (HbA1c) levels in patients with differing baseline HbA1c levels.

        Data were pooled from seven multicenter, double-blind trials in which overweight or obese type 2 diabetics treated with metformin, sulfonylurea, and/or insulin were randomized to treatment with orlistat, 120 mg, or placebo, tid, in addition to a mildly reduced-calorie diet (500 to 600 kcal/d deficit) containing approximately 30 percent of calories as fat, for up to one year.

        A total of 2,550 patients were randomized to treatment; 1,230 in the placebo group and 1,249 in the orlistat groups were eligible for intent-to-treat analysis.

        Results showed that the weight loss from baseline was significantly greater for patients treated with orlistat than for those in the placebo group (-3.8 percent versus 1.4 percent, respectively). The least squares mean (LSM) difference between the two treatment groups was -2.4 kg.

        In the whole intent-to-treat population, 1122 orlistat-treated patients had a significantly larger decrease in HbA1c than 1153 placebo recipients (-0.7 percent versus -0.3 percent). The LSM difference between the two treatment groups was -0.4 percent.

        In all subpopulations of patients with differing baseline levels of hemoglobin A1c, ranging from 7 percent or greater to 11 percent or greater), those treated with orlistat had greater reductions in HbA1c from baseline to end point (week 24 or 52) than placebo recipients.

        The LSM difference between the orlistat and the placebo groups for change in HbA1c level in patients with baseline level of 8 percent or greater was -0.5 percent. A significantly larger proportion of orlistat than placebo patients had reductions in HbA1c levels of 0.5 percent or greater from 8 percent or greater at baseline to less than 8 percent at end point (43.8 percent versus 27.8 percent).

        Orlistat is a non-systemically acting lipase inhibitor that has been shown to have multiple benefits in trials in overweight patients with type 2 diabetes, including improving glycemic control, decreasing weight, and improving other risk factors for cardiovascular disease.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send